Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate.
Ondrej FialaPetr HošekHana KorunkováMilan HoraJiří KolářOndřej ŠorejsOndřej TopolčanJan FilipovskýVáclav LiškaMatteo SantoniSebastiano ButiJindřich FínekPublished in: Cancer medicine (2024)
The findings of this study suggest an association between the concomitant use of ACEIs and longer survival of mCRPC patients receiving ENZ or ABI therapy.